The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Lutge, Elizabeth E ^a   Gray, Andy ^a   Siegfried, Nandi ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; MEDICAL CANNABIS; CANNABINOID; CANNABIS; TETRAHYDROCANNABINOL;

AIDS PATIENT; ANTHROPOMETRY; BODY COMPOSITION; BODY FAT; BODY WEIGHT CHANGE; BODY WEIGHT GAIN; CALORIC INTAKE; COMPARATIVE EFFECTIVENESS; DIETARY INTAKE; DISEASE DURATION; HEMATOLOGICAL PARAMETERS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INGESTION; KARNOFSKY PERFORMANCE STATUS; LOSS OF APPETITE; MOOD CHANGE; MORBIDITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; VOMITING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; PHYTOTHERAPY; WEIGHT GAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CANNABINOIDS; CANNABIS; HIV INFECTIONS; HUMANS; MORBIDITY; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAHYDROCANNABINOL; WEIGHT GAIN;

EID: 84886841078     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005175.pub3     Document Type: Review

References (23)

1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al.Short-term effects of cannabinoids in patients with HIV-1 infection: a randomised, placebo controlled trial. Annals of Internal Medicine 2003;139:258-66.
2. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al.Cannabis in painful HIV-associated sensory neuropathy: a randomised placebo-controlled trial. Neurology 2007;68:515-21.
3. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al.Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management 1995;10:89-97.
4. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gounaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomised, crossover clinical trial. Neuropsychopharmacology 2009;34:672-680.
5. Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 2005;181:170-8.
6. Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric intake, Mood and Sleep. Journal of Acquired Immune Deficiency Syndromes 2007;45:545-554.
7. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, et al.Effect of dronabinol on nutritional status in HIV infection. Annals of Pharmacotherapy 1993;27:827-31.
8. Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain research January 2012;1431:46-52.
9. Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G, and the DATRI 004 study group. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses 1997;13(4):305-15.
10. Abdool Karim SS, Abdool Karim Q (eds). HIV/AIDS in South Africa (2nd edition). Cape Town: Cambridge University Press, 2010.
11. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. Journal of Opioid management 2009;5(3):153-68.
12. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. Journal of Ethnopharmacolology 2006;105(1-2):1-25.
13. Bloom JW, Kaltenborn WT, Paoletti P, Camilli A, Lebowitz MD. Respiratory effects of non-tobacco cigarettes. British Medical Journal (Clinical Research Ed.) 1987;12(295):1516-8.
14. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. Journal of Pain and Palliative Care Pharmacotherapy 2009;23(1):4-25.
15. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences 2001;356(1407):381-408.
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley and Sons, 2008.
17. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al.Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology 2002;20(2):567-73.
18. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, et al.The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002;16:543-50.
19. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliviera LMQ, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer 2008;17:431-3.
20. Mechoulam R, Hanus L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Research and Management 2001;6(2):67-73.
21. Nutt DJ, King LA, Phillips LD, on behalf of the Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010;376(9752):1558-65. [DOI: 10.1016/S0140-6736(1)61462-6].
22. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology 2009;156:397-411.
23. Short communication. Marijuana in the 20th century: a chronology of use and regulation. International Journal of Drug Policy 1999;10(4):339-46.